Archer Materials Limited informed shareholders that the Company has implemented an early-stage prototype of an integrated biochip platform with automated liquid sample handling and readout. The work is a major milestone towards Archer's biochip technology commercialisation. The company's biochip innovation aims to integrate graphene field effect transistors ("gFETs") into advanced fluidic systems to create miniaturised lab-on-a-chip device platforms for medical diagnostics.

In particular, the integration of gFETs with on-chip fluidics to potentially enable multiplexing, i.e., the ability to parallelise the detection of multiple biologically relevant targets fluids, on a chip. The company has made significant technological progress over the last year that fundamentally link to the development of a prototype biochip technology system platform, recently designing and fabricating an operational liquid-gated gFET, i.e., a wettable transistor. For the first time, the company has now developed, built, and configured a method, device, and prototype operational system platform for lab-on-a-chip sensing of the electronic properties of biologically relevant fluid samples (Image 1).

This is a major milestone towards commercialisation of Archer's biochip technology.